Catalent Biologics - Device Assembly & Packaging

The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market

By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites

Catalent has the right scale and experience across a wide range of dose forms and geographies to meet your manufacturing needs and supply better treatments to your patients and consumers. Our broadest capabilities (oral, biologic, inhaled, sterile), unmatched tech transfer and product launch experience and scale in Branded, Generics, Over-the-Counter Medicines and Nutritional Supplements will meet your needs and drive growth throughout the product lifecycle.

The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services

Your therapy has so much potential—we have the passion to optimize it. Achieving preclinical formulation targets is only half the battle in successful drug development. Without solutions for compliance barriers and patient acceptance, outcomes for your drug may suffer. By applying advanced dose design principles early, we can help you achieve optimal absorption profiles as well as improve patient adherence and compliance, leading to greater payer acceptance, more scripts, and potentially better patient outcomes.

The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

Two 2,000-liter single-use bioreactors to be installed as part of first phase expected to be operational in April 2023

The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the leader in advanced therapy development for severe liver diseases, today announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline.

New facility at Gosselies site will host commercial scale pDNA manufacturing as Catalent extends its cell and gene therapy footprint

CPHI asks industry experts at Beximco Pharmaceuticals, Catalent, DIA and Thermo Fisher Scientific to weigh in on the remarkable innovations we have witnessed and what lasting impacts they may have on our industry in a post-pandemic world

With CPHI North America fast approaching, we ask Karen Flynn (President, Biologics & Chief Commercial Officer, at Catalent), Hamilton Lenox (Senior Vice President of Business Development, Sales & Marketing, at LGM Pharma), and Mike Kleppinger, Chief Commercial Officer, at AMRI) to weigh in on strategies the industry can use to build supply chain resiliency which ensure uninterrupted access to medicines

The company's custom single run single-use fermenters supplied on fast-track schedule to support flexible manufacturing of plasmid DNA

The extended collaboration comes after reaching the initial milestone of producing 100 million doses

The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders

The company acquires a pDNA CDMO and launches pDNA development and manufacturing services at its Rockville, Maryland facility

The CDMO will manufacture recently FDA-approved Lupkynis as a softgel dosage form at its St Petersburg, Florida, facility

The agreement allows the CDMO to "stay on the forefront of emerging indications and cell types"

The CDMO will provide packaging, labeling and distribution services through its FastChain demand-led supply offering

The agreement comes hot on the heels of FDA approval of Gavreto — Blueprint Medicines' new treatment for lung cancer

Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland.

Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the launch of its new OneXpress™ service for the integrated development, scale up and manufactur...